Glucagon-like peptide-1 receptor agonists and Wernicke encephalopathy: A pharmacovigilance study and literature review
Clinical Nutrition · 2026-02 · 57 · 106571
DOI: 10.1016/j.clnu.2025.106571 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Nutrition, 2026-02. Verfasst von Dana Lev und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Sheba Medical Center, Ramat-Gan, Israel. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Wernicke Encephalopathy, Pharmacovigilance, Hypoglycemic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: U.S. Food and Drug Administration.
Abstract (Originalsprache)
BACKGROUND & AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the treatment of type 2 diabetes mellitus and obesity in recent years. While gastrointestinal adverse events are common, their association with nutritional deficiencies, including thiamine, has not been comprehensively investigated. This study aimed to evaluate whether treatment with GLP-1 RAs is associated with the occurrence of Wernicke encephalopathy (WE). METHODS: We conducted a pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) and a narrative literature review. Disproportionality analysis assessed WE reporting following GLP-1 RA treatment using the reporting odds ratio (ROR) and the lower bound of the information component (IC) 95 % credibility interval. RESULTS: We identified 15 cases of GLP-1 RA-associated WE: 13 from FAERS, 1 from published literature, and 1 from our medical center. Most cases occurred with semaglutide (n = 8/15) or tirzepatide (6/15), and were reported in 2023-2024 (14/15). Most patients (13/15) reported gastrointestinal manifestations of either weight loss, vomiting, loss of appetite, or malnutrition. Classic WE symptoms were reported in 11 patients, and the full clinical triad in 2 patients. Long-term neurological sequelae were noted in 7 of 11 patients with follow-up data. Disproportionality analysis showed increased reporting of WE with GLP-1 RAs compared with other medications (ROR = 2.35 [95%CI, 1.38-4.01]; IC025 = 0.29). CONCLUSIONS: WE is a potentially rare but severe adverse event of GLP-1 RA treatment, mainly with semaglutide or tirzepatide. As early detection may prevent neurological sequelae, increased clinical awareness is warranted, especially in individuals experiencing severe gastrointestinal symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Sheba Medical Center, Ramat-Gan, Israel.
- Department of Internal Medicine, Sheba Medical Center, Ramat-Gan, Israel; Gray Faculty of Medical & Health Sciences, School of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Gray Faculty of Medical & Health Sciences, School of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Gastroenterology, Sheba Medical Center, Ramat-Gan, Israel.
- Department of Internal Medicine, Sheba Medical Center, Ramat-Gan, Israel; Gray Faculty of Medical & Health Sciences, School of Medicine, Tel Aviv University, Tel Aviv, Israel; Division of Endocrinology, Diabetes and Met…
- Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Ramat Gan, Israel; Department of Epidemiology and Preventive Medicine, School of Public Health, School of Medicine, Tel Aviv University, Tel Aviv…
- Department of Epidemiology and Preventive Medicine, School of Public Health, School of Medicine, Tel Aviv University, Tel Aviv, Israel; The Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Ce…
Förderung
- U.S. Food and Drug Administration
Zitieren
APA
Lev, D., Leibowitz, A., Lang, A., Shlomai, G., Twig, G., Eden-Friedman, Y., Engel, T., Cukierman-Yaffe, T., Dankner, R., Gerstein, H. C., & Goldman, A. (2026). Glucagon-like peptide-1 receptor agonists and Wernicke encephalopathy: A pharmacovigilance study and literature review. Clinical Nutrition, 57, 106571. https://doi.org/10.1016/j.clnu.2025.106571
Vancouver
Lev D, Leibowitz A, Lang A, Shlomai G, Twig G, Eden-Friedman Y, et al. Glucagon-like peptide-1 receptor agonists and Wernicke encephalopathy: A pharmacovigilance study and literature review. Clinical Nutrition. 2026;57:106571. doi:10.1016/j.clnu.2025.106571
BibTeX
@article{Lev2026,
author = {Lev, Dana and Leibowitz, Avshalom and Lang, Alon and Shlomai, Gadi and Twig, Gilad and Eden-Friedman, Yehudit and Engel, Tal and Cukierman-Yaffe, Tali and Dankner, Rachel and Gerstein, Hertzel C and Goldman, Adam},
title = {Glucagon-like peptide-1 receptor agonists and Wernicke encephalopathy: A pharmacovigilance study and literature review},
journal = {Clinical Nutrition},
year = {2026},
volume = {57},
pages = {106571},
doi = {10.1016/j.clnu.2025.106571}
}
EUVIMED